Possibility of the blood clot, thrombotic thrombocytopenia following injection of COVID-19-vaccine AstraZeneca; a systematic review

M. Momenzadeh, Ebrahim Moayedi, S. Dehghani, Shahrzad Shadabi, Mohammad Moein Derakhshan Barjoei, M. Mousavi, S. Pourrezaei
{"title":"Possibility of the blood clot, thrombotic thrombocytopenia following injection of COVID-19-vaccine AstraZeneca; a systematic review","authors":"M. Momenzadeh, Ebrahim Moayedi, S. Dehghani, Shahrzad Shadabi, Mohammad Moein Derakhshan Barjoei, M. Mousavi, S. Pourrezaei","doi":"10.34172/jpe.2023.34192","DOIUrl":null,"url":null,"abstract":"Introduction: Recently, it has been reported that the injection of vaccines such as the ChAdOx1 nCoV-19 (AstraZeneca) involves some rare cases of thrombocytopenia and blood clots, although the vaccines created immunity in people. Estimates of this phenomenon are not the same in different countries, probably due to age distribution and number. Objectives: This study attempted to study AstraZeneca’s rare side effects in people injected with this vaccine. Methods: This systematic study was conducted using articles published in 2021 under the title of blood clot and thrombocytopenia by AstraZeneca injection. The references and data were gathered through national and international sites such as Magiran, Google Scholar, PubMed, Web of Science, and Scopus. They were also gathered and examined using report cases and the available data on COVID-19 vaccine immunization in various countries. The keywords used mainly are COVID-19 vaccine, ChAdOx1 nCoV-19 vaccine, blood clots, thrombus, thrombotic, and thrombocytopenia. Eventually, 25 articles were searched and examined, of which 15 related ones were selected after reviewing and re-studying. While investigating the summary and method in those 15, they were filtered more accurately; finally, ten articles were chosen. Inclusion criteria consisted of all related articles and exclusion criteria contained articles that were less related to our research subject after purification or were redundant and not of high quality. Results: This study found that rare blood clot cases and thrombocytopenia were seen despite mild side effects after AstraZeneca injection. After assessing its benefits, adverse effects, and age distribution, the countries using AstraZeneca decided to continue using it. The main difference in reported statistics in these countries is due to the variety in the age and number of people receiving the vaccine. Conclusion: Blood clots and thrombocytopenia are among the rare side effects of the AstraZeneca vaccine. In different countries, the vaccine side effects vary depending on the age and number of participants. Anyway, according to the investigations conducted in this area, the highest records of these side effects are observed in Norway, which is still low. Overall, through studying this study and other similar ones, politicians, managers, and even ordinary people can be informed about the pros and cons of this vaccine.","PeriodicalId":91739,"journal":{"name":"Journal of epidemiology and preventive medicine","volume":"79 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of epidemiology and preventive medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jpe.2023.34192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Recently, it has been reported that the injection of vaccines such as the ChAdOx1 nCoV-19 (AstraZeneca) involves some rare cases of thrombocytopenia and blood clots, although the vaccines created immunity in people. Estimates of this phenomenon are not the same in different countries, probably due to age distribution and number. Objectives: This study attempted to study AstraZeneca’s rare side effects in people injected with this vaccine. Methods: This systematic study was conducted using articles published in 2021 under the title of blood clot and thrombocytopenia by AstraZeneca injection. The references and data were gathered through national and international sites such as Magiran, Google Scholar, PubMed, Web of Science, and Scopus. They were also gathered and examined using report cases and the available data on COVID-19 vaccine immunization in various countries. The keywords used mainly are COVID-19 vaccine, ChAdOx1 nCoV-19 vaccine, blood clots, thrombus, thrombotic, and thrombocytopenia. Eventually, 25 articles were searched and examined, of which 15 related ones were selected after reviewing and re-studying. While investigating the summary and method in those 15, they were filtered more accurately; finally, ten articles were chosen. Inclusion criteria consisted of all related articles and exclusion criteria contained articles that were less related to our research subject after purification or were redundant and not of high quality. Results: This study found that rare blood clot cases and thrombocytopenia were seen despite mild side effects after AstraZeneca injection. After assessing its benefits, adverse effects, and age distribution, the countries using AstraZeneca decided to continue using it. The main difference in reported statistics in these countries is due to the variety in the age and number of people receiving the vaccine. Conclusion: Blood clots and thrombocytopenia are among the rare side effects of the AstraZeneca vaccine. In different countries, the vaccine side effects vary depending on the age and number of participants. Anyway, according to the investigations conducted in this area, the highest records of these side effects are observed in Norway, which is still low. Overall, through studying this study and other similar ones, politicians, managers, and even ordinary people can be informed about the pros and cons of this vaccine.
阿斯利康注射covid -19疫苗后血栓性血小板减少的可能性系统回顾
最近,有报道称,注射ChAdOx1 nCoV-19(阿斯利康)等疫苗涉及一些罕见的血小板减少和血栓病例,尽管这些疫苗在人体内产生了免疫力。不同国家对这一现象的估计不尽相同,可能是由于年龄分布和数量的不同。目的:本研究试图研究阿斯利康在注射该疫苗的人群中罕见的副作用。方法:本系统研究采用发表于2021年的论文,标题为阿斯利康注射液引起的血栓和血小板减少症。参考文献和数据是通过Magiran、b谷歌Scholar、PubMed、Web of Science和Scopus等国内和国际网站收集的。还利用报告病例和各国COVID-19疫苗免疫的现有数据收集和检查了这些数据。关键词主要是COVID-19疫苗、ChAdOx1 nCoV-19疫苗、血凝块、血栓形成、血小板减少。最终,我们对25篇文章进行了检索和审查,其中15篇相关文章是经过审查和重新研究后选出的。在调查这15个人的总结和方法时,他们被过滤得更准确;最后选出了10篇文章。纳入标准包括所有相关文献,排除标准包括纯化后与我们研究主题相关性较低或冗余且质量不高的文献。结果:本研究发现,阿斯利康注射液虽有轻微副作用,但出现了罕见的血栓和血小板减少症。在评估了它的益处、副作用和年龄分布后,使用阿斯利康的国家决定继续使用它。这些国家报告的统计数据的主要差异是由于接种疫苗的年龄和人数不同。结论:血栓和血小板减少是阿斯利康疫苗罕见的副作用之一。在不同的国家,疫苗的副作用取决于参与者的年龄和人数。无论如何,根据在该地区进行的调查,这些副作用的最高记录是在挪威,但仍然很低。总的来说,通过研究这项研究和其他类似的研究,政治家,管理者,甚至普通人都可以了解这种疫苗的利弊。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信